Skip to main content
Signal8
Launch Terminal

NewAmsterdam Pharma Co N.V. (NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMSHealthcare
-3.37%$20.06
AH$20.00-0.30%vs close
Mkt Cap$2.4B
Float86.23M
O/S119.54M
Vol
$ Vol
RVOL
Inst Own101.9%
SI16.4%
Earnings
Dilution
NewAmsterdam Pharma Company N.V. logoNASDAQ:NAMS$20.06-3.37%
FormDescription
4
Statement of Changes in Beneficial Ownership
8-K
8.01,9.01
2
13D/A
Beneficial Ownership Report (Active, Amended)
8-K
8.01
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
144/A
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
8-K/A
5.02
2
3
Initial Statement of Beneficial Ownership
8-K
5.02
2
13G/A
Beneficial Ownership Report (Amended)
1
8-K
2.02,9.01
6
10-Q
Quarterly Report
6
8-K
8.01,9.01
2
8-K
5.02
2
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
S-8
SEC Filing
13G/A
Beneficial Ownership Report (Amended)
8-K
5.02,5.07,9.01
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities

1-25 of 412

…

Recent SEC filings with analysis